<SEC-DOCUMENT>0001193125-25-004119.txt : 20250110
<SEC-HEADER>0001193125-25-004119.hdr.sgml : 20250110
<ACCEPTANCE-DATETIME>20250110080108
ACCESSION NUMBER:		0001193125-25-004119
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250110
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250110
DATE AS OF CHANGE:		20250110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			scPharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001604950
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				465184075
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38293
		FILM NUMBER:		25520506

	BUSINESS ADDRESS:	
		STREET 1:		25 BURLINGTON MALL ROAD, SUITE 203
		CITY:			BURLINGTON
		STATE:			MA
		ZIP:			01803
		BUSINESS PHONE:		617-517-0730

	MAIL ADDRESS:	
		STREET 1:		25 BURLINGTON MALL ROAD, SUITE 203
		CITY:			BURLINGTON
		STATE:			MA
		ZIP:			01803
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d886285d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:scph="http://www.scpharmaceuticals.com/20250110" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-334">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-01-10_to_2025-01-10">0001604950</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="scph-20250110.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-01-10_to_2025-01-10"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001604950</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-10</xbrli:startDate> <xbrli:endDate>2025-01-10</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-345">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-01-10_to_2025-01-10" format="ixt:datemonthdayyearen" id="ixv-346">January&#160;10, 2025</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-347">scPharmaceuticals Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-01-10_to_2025-01-10" format="ixt-sec:stateprovnameen" id="ixv-348">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-349">001-38293</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-350">46-5184075</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-351">25 Mall Road</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-352">Suite 203</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-353">Burlington</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-01-10_to_2025-01-10" format="ixt-sec:stateprovnameen" id="ixv-354">Massachusetts</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-355">01803</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-356">(617)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-357">517-0730</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-01-10_to_2025-01-10" format="ixt-sec:boolballotbox" id="ixv-358">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-01-10_to_2025-01-10" format="ixt-sec:boolballotbox" id="ixv-359">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-01-10_to_2025-01-10" format="ixt-sec:boolballotbox" id="ixv-360">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-01-10_to_2025-01-10" format="ixt-sec:boolballotbox" id="ixv-361">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-362">Common stock, par value $0.0001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-363">SCPH</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-01-10_to_2025-01-10" format="ixt-sec:exchnameen" id="ixv-364">The Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-01-10_to_2025-01-10" format="ixt-sec:boolballotbox" id="ixv-365">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;2.02 Results of Operations and Financial Condition. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;10, 2025, scPharmaceuticals Inc. (the &#8220;Company&#8221;) issued a press release announcing preliminary financial information for the quarter and full year ended December&#160;31, 2024, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information contained in Item 2.02 of this Current Report on Form <span style="white-space:nowrap">8-K</span> (including Exhibit 99.1 attached hereto) shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;8.01. Other Events. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;10, 2025, the Company provided the below corporate update and preliminary unaudited financial results for the quarter and year ended December&#160;31, 2024: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Company expects preliminary unaudited fourth quarter FUROSCIX net revenue to be in the range of $12.0&#160;million to $12.3&#160;million, representing a 22% increase from the third quarter of 2024 at the <span style="white-space:nowrap">mid-point</span> of the range </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The <span style="white-space:nowrap"><span style="white-space:nowrap">gross-to-net</span></span> discount is expected to be in the range of 18% to 19%, compared to the <span style="white-space:nowrap"><span style="white-space:nowrap">gross-to-net</span></span> discount of 15.7% in the third quarter of 2024 </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Preliminary unaudited full year 2024 FUROSCIX net revenue is expected to be in the range of $36.2&#160;million to $36.5&#160;million, representing 167% growth over the full year 2023 at the <span style="white-space:nowrap">mid-point</span> of the range </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Approximately 13,300 FUROSCIX doses shipped in the fourth quarter, representing an approximately 23% increase from the 10,800 doses shipped in the third quarter of 2024 </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Added a specialty pharmacy to improve coverage of expanded geography </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Unaudited cash, cash equivalents and short-term investments were approximately $75.7&#160;million as of December&#160;31, 2024, which does not include an approximate increase in accounts receivable of 27% over the balance as of September&#160;30, 2024 </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These preliminary select financial results are unaudited and subject to change. The Company has not completed its financial closing procedures for the quarter or year ended December&#160;31, 2024 and its actual results could be materially different from these preliminary financial results. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Forward-Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on Form <span style="white-space:nowrap">8-K</span> contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form <span style="white-space:nowrap">8-K</span> that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the our anticipated financial results of the fiscal quarter and full year ended December&#160;31, 2024. Any forward-looking statements in this Current Report on Form <span style="white-space:nowrap">8-K</span> are based on management&#8217;s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include but are not limited to, our dependence on the commercial success of FUROSCIX and, if approved, our other product candidates; risks related to the receipt of regulatory approval for our product candidates; risks related to our ability to manufacture, or the ability of third parties to deliver, sufficient product for commercialization of FUROSCIX or any of our product candidates, if approved; risks related to our history of operating losses, we have a history of significant operating losses and expect to incur significant and increasing losses for the foreseeable future; we may never achieve or maintain profitability; we may need additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our product development programs or commercialization efforts; the terms of our credit facility place restrictions on our operating and financial flexibility, and we may not have cash available to us in an amount sufficient to enable us to make interest or principal payments on our indebtedness when due; clinical and preclinical development involves a lengthy and expensive process with an uncertain outcome, and any difficulties or delays in the commencement or completion, or the termination or the potential for the results from any clinical trials to support submission of </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sNDAs or comparable regulatory applications; and the risk that global economic factors and uncertainties will impact the Company&#8217;s operations. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the sections entitled &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2023, on file with the Securities and Exchange Commission, available at the Securities and Exchange Commission&#8217;s website at <span style="text-decoration:underline">www.sec.gov</span>, as well as discussions of potential risks, uncertainties and other important factors in the Company&#8217;s subsequent filings with the Securities and Exchange Commission. All information in this Current Report on Form <span style="white-space:nowrap">8-K</span> is as of the date of the release, and the Company undertakes no duty to update this information unless required by law. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;9.01 Financial Statements and Exhibits. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(d)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Exhibits </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exhibit 99.1 relating to Item 2.02 shall be deemed to be furnished, and not filed: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:7%"/>
<td style="width:90%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit&#160;No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d886285dex991.htm">Press Release of scPharmaceuticals Inc. issued January&#160;10, 2025</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:44%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:5%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:44%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">SCPHARMACEUTICALS INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: January&#160;10, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John H. Tucker</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">John H. Tucker</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">President and Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d886285dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g886285g51z32.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12&nbsp;million to $12.3&nbsp;million,
representing 99% growth over Q4 2023 at the <FONT STYLE="white-space:nowrap">mid-point</FONT> of the range </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Fourth quarter 2024 <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Gross-to-net</FONT></FONT> (GTN) discount expected to be in the range of 18% to 19% </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Preliminary unaudited full year 2024 net revenue expected to be approximately $36.2&nbsp;million to $36.5&nbsp;million, compared to
$13.6&nbsp;million for full year 2023 </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BURLINGTON, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE)</B> &#150; scPharmaceuticals Inc. (Nasdaq: SCPH) (the
&#147;Company&#148;), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced preliminary results for the fourth quarter and full year 2024, including fourth quarter 2024 net
FUROSCIX revenue and unaudited cash and cash equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We continue to see FUROSCIX net revenue growth driven by our ongoing expansion efforts,
including collaborations with top Integrated Delivery Networks and hospital systems, and the initial impact of our expanded field sales force,&#148; stated John Tucker, President, and Chief Executive Officer of scPharmaceuticals. &#147;As we enter
2025, we look forward to the first full quarter with our expanded sales force and anticipated further growth in Class&nbsp;IV heart failure patients. We anticipate additional growth with the implementation of the Medicare redesign and our upcoming
PDUFA date in March to expand the FUROSCIX indication to include chronic kidney disease patients. We expect a <FONT STYLE="white-space:nowrap">mid-year</FONT> submission of the sNDA for our Autoinjector product candidate which should accelerate
future growth.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Updates and Preliminary Unaudited Q4 and FY 2024 Financial Results: </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">scPharmaceuticals expects preliminary unaudited fourth quarter FUROSCIX net revenue to be in the range of
$12&nbsp;million to $12.3&nbsp;million, representing a 22% increase from the third quarter of 2024 at the <FONT STYLE="white-space:nowrap">mid-point</FONT> of the range </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">gross-to-net</FONT></FONT> discount is
expected to be in the range of 18% to 19%, compared to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">gross-to-net</FONT></FONT> discount of 15.7% in the third quarter of 2024 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Preliminary unaudited full year 2024 FUROSCIX net revenue is expected to be in the range of $36.2&nbsp;million to
$36.5&nbsp;million, representing 167% growth over the full year 2023 at the <FONT STYLE="white-space:nowrap">mid-point</FONT> of the range </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Approximately 13,300 FUROSCIX doses shipped in the fourth quarter, representing an approximately 23% increase
from the 10,800 doses shipped in the third quarter of 2024 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Added a specialty pharmacy to improve coverage of expanded geography </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Unaudited cash, and cash equivalents were approximately $75.7&nbsp;million as of December&nbsp;31, 2024, which
does not include an approximate increase in accounts receivable of 27% over the balance as of September&nbsp;30, 2024 </P></TD></TR></TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g886285g51z32.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:14pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These preliminary select financial results are unaudited and subject to change. scPharmaceuticals will report
its final and complete fourth quarter and full-year 2024 financial results in March 2025. The Company has not completed its financial closing procedures for the quarter or year ended December&nbsp;31, 2024, and its actual results could be materially
different from these preliminary financial results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About scPharmaceuticals </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At scPharmaceuticals, we are powered by passion, driven by patient care. Our Mission is focused on advancing cardiorenal care through innovative, integrated
treatments that address unmet patient needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our goal is to become the foremost advocate for patient-centric cardiorenal care, driving global health
improvements through specialized, multidisciplinary approaches. scPharmaceuticals is expanding its reach, offering integrated therapies and products that address diverse healthcare needs and potentially improve the lives of our patients.
scPharmaceuticals is headquartered in&nbsp;Burlington, MA.&nbsp;For more information, please visit&nbsp;www.scPharmaceuticals.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking
Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our anticipated financial results of the
fiscal quarter and full year ended December&nbsp;31, 2024; our commercial strategy for FUROSCIX and anticipated sales; the impact of our ongoing expansion efforts including our expanded sales force; anticipated additional growth with the
implementation of the Medicare redesign; the PDUFA target action date related to the NDA seeking to expand the FUROSCIX indication to include the treatment of fluid overload in CKD; the potential submission of the sNDA for the Autoinjector; and the
timing of any of the foregoing. Any forward-looking statements in this press release are based on management&#146;s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to
differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include but are not limited to, our dependence on the commercial success of FUROSCIX and, if approved, our other
product candidates; risks related to the receipt of regulatory approval for our product candidates; risks related to our ability to manufacture, or the ability of third parties to deliver, sufficient product for commercialization of FUROSCIX or any
of our product candidates, if approved; risks related to our history of operating losses, we have a history of significant operating losses and expect to incur significant and increasing losses for the foreseeable future; we may never achieve or
maintain profitability; we may need additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our product development programs or commercialization efforts; the terms of our credit facility
place restrictions on our operating and financial flexibility, and we may not have cash available to us in an amount sufficient to enable us to make interest or principal payments on our indebtedness when due; clinical and preclinical development
involves a lengthy and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g886285g51z32.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:14pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expensive process with an uncertain outcome, and any difficulties or delays in the commencement or completion, or the termination or the potential for the results from any clinical trials to
support submission of sNDAs or comparable regulatory applications; and the risk that global economic factors and uncertainties will impact the Company&#146;s operations. For a discussion of these and other risks and uncertainties, and other
important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the sections entitled &#147;Risk Factors&#148; in the Company&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended&nbsp;December 31, 2023, on file with the&nbsp;Securities and Exchange Commission, available at the Securities and Exchange Commission&#146;s website at&nbsp;www.sec.gov, as well as
discussions of potential risks, uncertainties and other important factors in the Company&#146;s subsequent filings with the&nbsp;Securities and Exchange Commission. All information in this press release is as of the date of the release, and the
Company undertakes no duty to update this information unless required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Katherine Miranda </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">scPharmaceuticals Inc., <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">781-301-6869</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">kmiranda@scpharma.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nick Colangelo </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gilmartin Group,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">339-225-1047</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nick@GilmartinIR.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>scph-20250110.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 1/10/2025 5:51:23 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2024"
  xmlns:scph="http://www.scpharmaceuticals.com/20250110"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.scpharmaceuticals.com/20250110"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" namespace="http://xbrl.sec.gov/naics/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="scph-20250110_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="scph-20250110_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>scph-20250110_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 1/10/2025 5:51:23 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>scph-20250110_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 1/10/2025 5:51:23 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="scph-20250110.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g886285g51z32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g886285g51z32.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M">MSX@L=2LYO"_AF.74K)[<QW<#6]MH1EB,;[2L@V,NUB,$8.*^B;G_@J?\
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M^IY#G6$Q>+A&BWHT[N,DEJNK21^29]DN+PF#G*LEJFDE*,F].T9-_IYGPO\
M\$X?V;/VW_BS^P9X//PF^-7@/P;\+=2COX=-TZXC\O4K)1?W"7!\U=/DE5FG
M$SJRSD@,N"O 'U-^QY_P;V?#OX+^-K+QU\3]>USXN>/(IFNY&U.3;I8N?,61
M)C$=TLTBX()FE:-MQ)B!QM]<_P""'_P\\0?"G_@F#\,_#_BG0M7\-Z]IYU47
M6G:G9R6EU;[]6O9$WQ2*KKN1E89 R&!Z&OJ]N17TV89I6]K5A2:BFW\*2NK]
M6M[GS.7Y10=&G4JIR=E\3;MIVZ6/RA_X./AM_:%_9(& !_PD&I8'_;SH]?JT
MJ+M'TK\TO^"_7P(\;_&+XY_LOWGA'P=XJ\4VN@:[?RZG-I&DW%]'IR-/I3*T
M[1(PB!$4A!? .QO0U^ET397\.AK'&2C+!T(IZKF_]*-<#%K'8B36[C;_ ,!/
MS+_9+T6U\/?\'+_[15O9PK;PMX&BN611P9)4T&21OJSNS'U)K/\ $O\ P6=^
M.?[4_P"UIXF\!_LG_#?P?XV\/^$8,WFJ>(O,A^U%9A$]PCM=6\:1;F 2,[I'
M5&<<95.^_9V^#?B[1_\ @X;^._CB\\*^(K3P;K'@BUL[#79]-GCTV^F$&A Q
MQ7)012.##*"%8G,;C^%L?,'[/_P6_:,_X(5?M(?$)O"OP;UKXS?"WQ8Z0V\^
MD,9;BYA@\U[25C!%++!)&L\J2!X CMNVDC8Q]9QHU9W?+*:IPLF]&[*_5:_,
M\A2K4H<JYHP=2=VEJE?3H]&+_P %8_C#^VQKO[%/B/3OC-\*_A7HGP_O+BR%
M]JFA7>^\LY%NX6AV@ZA(27D"H2(V 5FSMX8;'_!8$#_B'Y_9;Z,,^%,<?]2Y
M=U5_;Z\>?MM?\%'?V9/$-N?@*OP]^%]JJZI>:9<2*VOZD('641".=DF?:"L@
M6.VC9S"5!8D1GM_^"I7P$\=?$[_@AG^S;X8\,^"?%WB+Q)I'_",M?Z5IFBW-
MU?60CT&ZBD:6"-"\861E4EE #, <9KHI3C!T%+EC:;NHO1:+?5_F85*<I_6'
M#FDG!6<EJ]>FBT/T3_8O4?\ #'GPG_[$[2.__3E#7Y@_LB1+-_P<U_%-6&Y?
M^)MQZ_N(:_4G]D?1KSPW^RG\,]/U"UN+&_T_PII=M<VUQ&8Y8)4M(E='5L%6
M5@00>017YZ?LN?LO_$;PO_P<'?$;X@:CX*\26/@?4/[2^S:Y/8R1V,^^&)5V
MR$;3DJ0,<&O'P,XQ^LW>\7\]3V<;3DUAK)Z27Y'T)_P7_M(I?^"3?Q2=XU:2
M%](>,L,E#_:]D,CT."1D=B:?_P $!HU_X=)_"?('_,7&/^XQ?#^7%;__  6N
M^%OB3XT_\$S?B1X;\(Z)J7B+Q!J1TO[+I]A TUQ<;-5LY'VHO)VHC,?0*31_
MP13^%_B/X+_\$R?AKX;\6Z+J7ASQ!I?]J?:M/OX&@N+??JMY(FY& (W(ZL,]
MF!K'FC_9JA?7GV\N7L;*,O[3<^G)O\^Y\C_$JUC@_P"#J+X>LBJC3Z%+)(1_
M&W]A7ZY/OM &?0"O2OVL_P#@K-\7-8_;3U+X$_LO_#C1?'?B[PC!+-XCN->(
M6TVH(=WD-]JMU18FF$;M*PW2,%5> S8/Q"^!GC>__P"#DSP)XZA\&^+)?!-C
MH<L,_B!-(N&TJ)SH]]&%:YV>4IWNB8+?>91U(KSGXQ_ 'X^?\$R_^"I'C_X\
M_#'X4WGQ<\#_ !&\Z.Z@MGENK^-;R6*[N81'#F:%UN(&V2&&6(1,@Y<X7U(Q
MHU9PYK2:IJR;TOV>WW7/)<JU*$^6\8NJ^9I:\MMUOUMJ8/\ P53^+7[<'B#]
MA7QI8_%[X8?"C1?AU=/8+K&H:)<[[VT O[=H2@:_DR&N%B0XC<[9#P!EUN03
M-9?\&ES21LT3X9,J^W(/C'!'T()!'<'%;7[4GQ3_ &S/^"L'P$\0>!=#_9QM
M_AKX!UF%)+]_$=\T.JSS6KB\C2%K@VQ EE@BC7%LRY?YI$7++]"_\$QOV5E^
M+7_!$+PW\)_B!I6M>'_^$ATW6]/OK:XMS:WVG^=JMZT4P25?ED0F.1 ZD9"D
M@C@U4K1I4*;J**<:B;47?2W75DTJ+K8B:IN;3@TG)=?+1'<_\$.;'1]/_P""
M6/PCCT>7SK1["ZEE);/^DM?7#7 / ^[,9%QVP!SP3]9':5Z_3GO7Y#_L_P"E
M_MK?\$>=.U#P3:_#*/XY?"'3;UFTDZ1*&N%1RT\AMEB+7,.]I'WK/!(JR+^[
M)#%I/JC]C/\ X* ?'K]J?XZ:1IOB#]F?Q#\)_!!AN)=4U?7;N9IE*1OY:QQS
M06[9>7RQ]Q_E#'&"&7S,PP,I59XBG*,HMMWNMM[6O>_E8]3+\?"-*&'G&49)
M*-K/?:][6MYGY>_\$8/BS^U)X8G^*FI?L_?#_P &_$:[URYL)?%$^OWT<,UM
M(#=M 45KVVX<R7!) ?E>H[_2W[9.@_\ !0S]N']G_5?AWXR_9Y^&$&BZI-!<
M?:-.U>SCN[:6&59%:)I-6D12=I4Y1LJS#'.1O>/OV-?VEO\ @EQ^UIXZ^(W[
M-N@:9\1/AG\0KS^UM<\-SQPFXM"LLKB )NCG98VN9O(:V+87 E1M@+]QIW_!
M8G]ISQC"VDZ3^Q#\0;/7)H_*AN]2N[R&QBE^[O<RV,2[ ><&9>/XAUKV<1B)
M5*RQ&&A3EMJW:2LDM?>7X+8\:AAXTZ+P^(E4COHE=.[;TLG^9X;_ ,%!/@]X
MV_9^_P"#=[X6^"_B)ITFD^+O#_BQ;:\LWNHKHV\?VC4VMU\R)W1A]G:+&UC@
M8'4$5^FW_!.HX_X)^? W_LGV@_\ IN@K@_\ @J)^Q]KW[>/[!>M>!],72;7Q
MG+)8ZEI_VZ9X+6&[AF1I5+*'(#0F=%ZC+KE@,L/C/]EK]N7]M#]F?X6Z)\%=
M4_95UCQ-KWANTAT#0-;5);32K6&!/*A^U3QA[69555'F+<0@JH)).7/G-2Q>
M$M%KF4Y-IM+>VJN]CT^:.#QG-)/E<(I.S>W1V1@?\%(AG_@XX^ ;?PY\/<_]
MOUS3?^"Q/_*P#^RW_P!RI_ZD=W6-XH_9._:J\<?\%/\ ]GSXS?&;PAI[WFM>
M(+6*YLO"EG+>6_@ZSLKF/"WLL0EBB63SGD1FN)21YF67:5'M'_!</]AGXM^,
M_P!IGX7_ +1'PBT1?&&K?#I+&*XT5%\RXC>TOWO;:98,JTT9DE99$1MX 4A<
M;F7T85*<*M&#FM*<HW3TOKI?U/.J1J5*-::@_P")&5K.]M.A^GN !Q_.ORE_
MX-PSC]H#]KG_ +&#3O\ TIUBOK__ ()Q_MN_$/\ ;'@\7#Q]\"?%WP5;PV+(
M61UL7(76S,)_-,(FM8,"+R4R 7_URYV\9^:?^" OP+\;_"'XX_M0W7B[P;XJ
M\*VOB#7;"72YM8TFXLH]11;C52S0M*BB50)(R2A(PZ^H)\BA'V.%Q%*=K^[I
M=:^\GIW/7Q$_;8G#58)V][HU;W>O8X7_ (-M#<>*_P!HS]JCQ#KD2W'B:;5]
M/:ZNY47S]\]UJDEP"P_OR1JQQP2B^@K]:B%V]MOZ5^47QS_8._:7_8*_X* ^
M./CI^SCI.C^.M!^($E[?:KHM]<I))'Y[)<W$<T+/ 7!N3(\!MW:0*"C?>;S.
MWM/^"N7[57C'.BZ-^Q3XQL?$C+M6]U6[NHM-#=<DR6L*8YZ>>/K6V8X=XJK]
M9HR3C)+3F2:LDK--HPRW%+"4OJM>+4DWLFT[N]TTCNO^"FO_  5*\>?LW_M&
M>"O@C\%_ MAXX^*7C*W2_1=3RUC##))*J1A4FC;?M@FD=Y'CCBC57)8%MGE/
MQS_: _X*)1? [Q5<>)/@O\%+703H=T=6\J]\R>VM?);SV _M,JS)'N. &W8Z
M-T,W_!3[]F/XV_!C_@I-X*_:F^#_ (#C^(UKX;T/[+JNE).9;L2A;BUD"VZE
M97$EM=+Y9@$I62-V=-H >KXO_;H_;&_;W\(:QX#\"?LLR?#?3=?LI]&UK5?&
MTMQ&EM!<*T#S0&=+3)C#LQ"1W##;_JVZ'>C1IQITI48PDK>\Y/5._JK>6AS5
MJU256I"M.<7>T5%:-6]-3=_X-:RQ_P""?WC++,V/B%>CDY_YAVFUYA_P:L:?
M#JWPL^.-K<)YD%S>:7%(N2-RM%=@C(YZ'M7N7_!N#\'O%7P+_8M\;Z#XQ\.:
MSX9UJ/X@7Q:TU&U>"1E%CI\>]=P ="R. ZY5MIP37G__  ;-? 7QY\"/ OQ<
MA\<>"?%O@V;4[W3'M8]=TBXTUKD)'<[B@F1=X4LH)7(!8>M&.JP;Q=FM91MY
MZ] P-.=L'=/2,K_=U/._@)^S7^VQ_P $FO%WQ#\+_!OX<^%?B1\.]<UL7>EZ
MEJMW!<-)&$81RB-+NUFCD:,HLV]"@>'$>%^>3OOAS_P75^*W[.W[1.E^!OVM
M/A;I/P[L=>@2:VU71H9O+LT=]BRR*T\ZRQ!E?>T;[DP/E8\5U_Q%_P""I7[6
M/[/WQ@\5:'X@_9*USQYH=OJ,\>AWWA6*]"2V@<F"266*.]C9FB*$@>7AMP*J
M05'SU^T7\$OVIO\ @N1\7O!<?BSX2O\ !GX6>';Z5#)K)\B\T^.58_/E=;@)
M<7$A$6V();I'N9 Q4;I!M&*KMRQL86:NY*2O>VFB;U\K&,I2H)0P4YW3LHN.
MFKUULM/F?M,IRHQR**1.$'THKY,^R%QFC&:\1_:B_:3\>?"?XF^$/"/P]^&N
MF_$76O$VDZMK4T=[XH70DLK>PFT^)MK-;S"1G;4$P#MQL/)SQ0^!?_!03PCX
M_P#V7])^)7CJZT7X51W>I7>AWMEKNM0+'9ZC:SSP2VR7!*I.Q-O(Z%.709 R
M"!M]7J<BJ):>6OX;]##ZQ34W!NS\].W7;JCWS:,]!^5&Q?[H_*N)\!_M'> _
MBE86=WX9\;>$?$%IJ&H/I%M+IVK072S7J0&X>U78YS.L*M(8OOA%+$  FM8?
M%/PZUUXBA_M[1!+X1VMKB&]CW:.K0K.#<C=^YS$PD!DV_(0WW>3GR23LT:1J
M1>J9T..*38N?NC\J\V^(_P"V#\+?@YJEG8^+OB1X#\-WE_:)J$$.I:[;6KRV
MKLRQW 5W!\IF4J)/N%A@,3@'0U?]ISX=>'_%&A:'?^/O!-EK7B>.VFT>PGUN
MVCNM62X9EMWMXR^Z9961PA0$,5;&<&G[.>]F+VU/:Z.ZZ45YC!^VE\([KXD-
MX/C^)W@%O%"W[:5_9/\ ;UK]L:]5PC6JQ^9N,ZN0IB W@D @4[XE_ME?"?X.
M>)Y-#\6?$SP#X9UJWC6:>QU37K6UN+:-AE7E1W!C1LC#-@$L #DBG[&I>W*^
M^W3N+VU.U^9?>>E[%S]T?E2XP:\Q^&O[1G_"POV.M"^+7]C_ &3^VO!\'BS^
MRS=;O(\VR6Z^SF8H,XW;-^P9QG:.E<K^SQ_P42^%OQZ^&_@74_\ A._A_I/B
M3QK86$P\.'Q/:3WMK>W,$<IL NY7DF1GV;=@8D?='2CV,[-VV=A>WIW6NZNC
MW?:/0?E0% [#\JYYOBKX<C\,:QKC>(="_L7P\;E-6O\ [=&+73&MBPN1/+NV
MQ&+:V\.1LVG=C!Q<\4>-]+\":(^I:[JFFZ/IZ310&YO;A;>$22R+#$A=R%W/
M*Z(HS\S.JC)(SGRO:QISQWN:I16'*C\J4* >E<3\-?VD?A_\:-0FL_!OCKP;
MXLN[:W2[FAT?6K:^DBA<X25EB=B$8@@,1@D=:P+W]N+X.Z;XPO/#MQ\5/AW#
MKFG3S6MU92^(;6.:":#/GPL"_$D85BZ'YD"G(&*M4IMV47]S)=:FE=R7WH]5
M"A1P*",UY_>?M5?#?3?BY)X"N/'G@^#QG%$T[Z))JT*WR(L/VAB8BVX$0$2D
M8R(_GQM^:L'P[^V-X0^*]UH;_#GQ5\//&VGWFMC2-4N(/%,*-8;K>>9?*1$D
M\^9O).V'*;DW.&VHU/V4WK9B]O3VNCU[%&*\Q_X;0^$B_$7_ (1!OBA\/E\5
M?;O[+.DG7[7[8+PR>6+3R]^[[06^7RL;\_P\&I/'/[8OPI^&'B74-%\2?$OP
M#H>L:0$;4+&^UZUM[C3U=4=&G1W#1*RR1X9P ?-CP?G4%>SG>UG]P_;4][K[
MSTDHI/W1^5&T9Z#\J9'(63/]*^?_ (\?M3?%+PI\=]6\#_#/X0Z3\19M!\-Z
M?X@OKB\\9)H;+]LN-0AB@1'M90Y_XE\AW%U'S@$#K2IP<W9?CI^85*D8*\O\
MSZ$QQ1M'I7B/PL_;<T'5OA_JE_\ $G^R?@]XD\+W$=GXET3Q#KEJ/[$EE3SH
M,W080RQRPD.DB$JQ61.'BD5>G\"_M$:7XL\9WVFSZMX)BM[R]BMO#3V?B6*\
MNM>5K!+YF\C8OEMY+-(J(\I:%?-^5"*J5&<;W6Q,<13E;E>YZ,JA1P ._ H*
M*3G:/RKDM6^.W@S09_$\-]XO\*V4O@J&&Y\0I-JD$;:#%,K/%)=@N# KHK,K
M2;0R@D9 )K(\)?M;_"_QUX>US5M)^(G@G4--\,Q?:-8N(M9MRFD18)\RY^?]
MRI"L0TFT$#/3FI]G)J]F5[2"=KH]$"@=A^5*1FN#\%?M.?#WXC>+AH&@^.?"
M.M:VT+W"6-CJL$]Q+$C;))$17)=$8%69<A6X.#Q6/\7_ -K+PW\!_C)X5\,^
M+=2T'P[I?B?1=4U1=9U758K&".:SN=,@2V7S,*[R_P!HEA\X(\C 5MQ*U[.;
MERV=P]M#EYKZ=SU,* >@_*EVC/2N(\*_M(> ?'>C1ZEH?CCP;K&GS:J-#2ZL
M=9M[B%[\@-]D#HY!N-I!\K[_ ".*Z6#Q9IUSXCN-'CU"QDU>SMHKVXLEG4W$
M,$KRI'*T>=RH[PRJK$8)B< DJ<0XM;HI3B]F:6,T@4 =!7GGC7]K3X7_  TU
MZ\TOQ)\2/ /A_4M/+"ZM-1U^UM;BVVQ13-O220,N(IX9#D#"S1GHRDZ'CS]H
MGP+\+_ >G^*/$7C/PKH?AS6&C33]3OM4A@M=0:2-I(UAD9@LK.B,RJF2RJ2
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M=E::=#I5G>73)L;$T@V(2Z(KF1F7],C&I[4!%7H*J..FEM_6FGX$RRV#>_\
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MPIJ>AW=Y9VVGO'-I;RV,\=_+,N-R,QNKE9G<9+3ON.6)KZT"*%"XX'0>E+L
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<N1UK.MB74BDT:T<&J4G)/^KCE.5%%%%<QV'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45482358756672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 10, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001604950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 10,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">scPharmaceuticals Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-5184075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">25 Mall Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Burlington<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">01803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">517-0730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SCPH<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MH@>Z>G<XWS6LRHH#\4)9.%X7EVO.8!VX!^#WI5+VK>'.V.5?)*/O4$L#!!0
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MX_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0
M   ( "- *EH'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ (T J6@S/N_CM    *P(  !$
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M;',O+G)E;'-02P$"% ,4    "  C0"I:'#AEZC\!   \ @  #P
M    @ %G$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ (T J6B0>FZ*M
M    ^ $  !H              ( !TQ$  'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ (T J6F60>9(9 0  SP,  !,
M ( !N!(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @   A0
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d886285d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d886285d8k.htm">d886285d8k.htm</File>
    <File>scph-20250110.xsd</File>
    <File>scph-20250110_lab.xml</File>
    <File>scph-20250110_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d886285d8k.htm": {
   "nsprefix": "scph",
   "nsuri": "http://www.scpharmaceuticals.com/20250110",
   "dts": {
    "inline": {
     "local": [
      "d886285d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "scph-20250110.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "scph-20250110_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "scph-20250110_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-01-10_to_2025-01-10",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d886285d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-01-10_to_2025-01-10",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d886285d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.scpharmaceuticals.com//20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-25-004119-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-004119-xbrl.zip
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M]0H=1T(N8I2HD+8U$PG.-B,#[)P _U2)_<T1Z0G^ZN-?B/ 7BWFQ&-+EX#$
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M6Q&;XNFV4?]-7K;4@5H_]5T:LVZ<]OZ ?=V8N5IA].<PME LM[A$>&\_?%3
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MT4%J[K' /@J[.6+?[(.=6/(W4$L! A0#%     @ (T J6D/C^:BE%@  BHH
M  X              ( !     &0X.#8R.#5D.&LN:'1M4$L! A0#%     @
M(T J6N>9'6T2#P  %3L  !$              ( !T18  &0X.#8R.#5D97@Y
M.3$N:'1M4$L! A0#%     @ (T J6L;QB8Q" P  9PL  !$
M ( !$B8  '-C<&@M,C R-3 Q,3 N>'-D4$L! A0#%     @ (T J6K9SHM1Z
M!@  N48  !4              ( !@RD  '-C<&@M,C R-3 Q,3!?;&%B+GAM
M;%!+ 0(4 Q0    ( "- *EH9L;,WQ00  %$L   5              "  3 P
M  !S8W!H+3(P,C4P,3$P7W!R92YX;6Q02P4&      4 !0!  0  *#4

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>d886285d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="scph-20250110.xsd" xlink:type="simple"/>
    <context id="duration_2025-01-10_to_2025-01-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001604950</identifier>
        </entity>
        <period>
            <startDate>2025-01-10</startDate>
            <endDate>2025-01-10</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-334">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-01-10_to_2025-01-10"
      id="Hidden_dei_EntityCentralIndexKey">0001604950</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-345">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-346">2025-01-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-347">scPharmaceuticals Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-348">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-349">001-38293</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-350">46-5184075</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-351">25 Mall Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-352">Suite 203</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-353">Burlington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-354">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-355">01803</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-356">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-357">517-0730</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-358">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-359">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-360">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-361">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-362">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-363">SCPH</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-364">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-01-10_to_2025-01-10" id="ixv-365">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
